Local generation of kynurenines mediates inhibition of neutrophil chemotaxis by uropathogenic Escherichia coli

Infection and Immunity

Volumn 84, Issue 4, 2016, Pages 1176-1183

  Loughman, Jennifer A ^a,b   Yarbrough, Melanie L ^a   Tiemann, Kristin M ^a   Hunstad, David A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STERIS Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN; AHR PROTEIN, MOUSE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CELL MIGRATION; CELL PROLIFERATION; CYSTITIS; ENZYME INDUCTION; ENZYME MECHANISM; FEMALE; HUMAN; HUMAN CELL; LONGEVITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORMAL HUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UROPATHOGENIC ESCHERICHIA COLI; ANIMAL; BLADDER; CELL CULTURE; CHEMOTAXIS; CYTOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MICROBIOLOGY; NEUTROPHIL; PHYSIOLOGY;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELLS, CULTURED; CHEMOTAXIS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MICE; NEUTROPHILS; RECEPTORS, ARYL HYDROCARBON; TRANSCRIPTION, GENETIC; URINARY BLADDER; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84962921329     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01202-15     Document Type: Article

References (52)

1. Mellor AL, Munn DH. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762-774. http://dx.doi.org/10.1038/nri1457.
2. Hwu P. 2000. Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596-3599. http://dx.doi.org/10.4049/jimmunol.164.7.3596.
3. Mellor AL. 2003. Cutting edge: induced indoleamine 2, 3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171:1652-1655. http://dx.doi.org/10.4049/jimmunol.171.4.1652.
4. Munn DH. 2002. Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 297:1867-1870. http://dx.doi.org/10.1126/science.1073514.
5. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. 2002. T cell apoptosis by tryptophan catabolism. Cell Death Differ 9:1069-1077. http://dx.doi.org/10.1038/sj.cdd.4401073.
6. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363-1372. http://dx.doi.org/10.1084/jem.189.9.1363.
7. Teske S, Bohn AA, Hogaboam JP, Lawrence BP. 2008. Aryl hydrocarbon receptor targets pathways extrinsic to bone marrow cells to enhance neutrophil recruitment during influenza virus infection. Toxicol Sci 102:89-99.
8. Zhang P. 2002. The GCN2 eIF2α kinase is required for adaptation to amino acid deprivation in mice. Mol Cell Biol 22:6681-6688. http://dx.doi.org/10.1128/MCB.22.19.6681-6688.2002.
9. Grohmann U, Fallarino F, Puccetti P. 2003. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24:242-248. http://dx.doi.org/10.1016/S1471-4906(03)00072-3.
10. Stone TW, Darlington LG. 2002. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609-620. http://dx.doi.org/10.1038/nrd870.
11. Moffett JR, Namboodiri MA. 2003. Tryptophan and the immune response. Immunol Cell Biol 81:247-265. http://dx.doi.org/10.1046/j.1440-1711.2003.t01-1-01177.x.
12. Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA, Pruitt IE, Rhee EP, Colvin RA, Gerszten RE. 2009. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 284:19189-19195. http://dx.doi.org/10.1074/jbc.M109.024042.
13. Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B. 2009. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206:43-49. http://dx.doi.org/10.1084/jem.20081438.
14. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M. 2011. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197-203. http://dx.doi.org/10.1038/nature10491.
15. Denison MS, Nagy SR. 2003. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309-334. http://dx.doi.org/10.1146/annurev.pharmtox.43.100901.135828.
16. Perdew GH. 1988. Association of the Ah receptor with the 90-kDa heat shock protein. J Biol Chem 263:13802-13805.
17. Ma Q, Whitlock JP, Jr. 1997. A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2, 3, 7, 8-tetrachlorodibenzo-pdioxin. J Biol Chem 272:8878-8884. http://dx.doi.org/10.1074/jbc.272.14.8878.
18. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. 2014. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol 32:403-432. http://dx.doi.org/10.1146/annurev-immunol-032713-120245.
19. Hao N, Whitelaw ML. 2013. The emerging roles of AhR in physiology and immunity. Biochem Pharmacol 86:561-570. http://dx.doi.org/10.1016/j.bcp.2013.07.004.
20. Nguyen NT, Nakahama T, Le DH, Van Son L, Chu HH, Kishimoto T. 2014. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol 5:551.
21. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. 2008. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 10:2568-2578. http://dx.doi.org/10.1111/j.1462-5822.2008.01230.x.
22. Hagberg L, Hull R, Hull S, McGhee JR, Michalek SM, Svanborg Eden C. 1984. Difference in susceptibility to Gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun 46:839-844.
23. Loughman JA, Hunstad DA. 2012. Induction of indoleamine 2, 3-dioxygenase by uropathogenic bacteria attenuates innate responses to epithelial infection. J Infect Dis 205:1830-1839. http://dx.doi.org/10.1093/infdis/jis280.
24. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105-107. http://dx.doi.org/10.1126/science.1084550.
25. Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ. 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282:1494-1497. http://dx.doi.org/10.1126/science.282.5393.1494.
26. Hultgren SJ, Schwan WR, Schaeffer AJ, Duncan JL. 1986. Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli. Infect Immun 54:613-620.
27. Blattner FR, Plunkett G, III, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y. 1997. The complete genome sequence of Escherichia coli K-12. Science 277:1453-1474. http://dx.doi.org/10.1126/science.277.5331.1453.
28. Hung CS, Dodson KW, Hultgren SJ. 2009. A murine model of urinary tract infection. Nat Protoc 4:1230-1243. http://dx.doi.org/10.1038/nprot.2009.116.
29. Loughman JA, Hunstad DA. 2011. Attenuation of human neutrophil migration and function by uropathogenic bacteria. Microbes Infect 13: 555-565. http://dx.doi.org/10.1016/j.micinf.2011.01.017.
30. Lau ME, Hunstad DA. 2013. Quantitative assessment of human neutrophil migration across a cultured bladder epithelium. J Vis Exp 2013: e50919. http://dx.doi.org/10.3791/50919.
31. Lokuta MA, Nuzzi PA, Huttenlocher A. 2007. Analysis of neutrophil polarization and chemotaxis. Methods Mol Biol 412:211-229. http://dx.doi.org/10.1007/978-1-59745-467-4_14.
32. Whitlock JP, Jr. 1999. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39:103-125. http://dx.doi.org/10.1146/annurev.pharmtox.39.1.103.
33. -δδCT method. Methods 25: 402-408. http://dx.doi.org/10.1006/meth.2001.1262.
34. De Ravin SS, Zarember KA, Long-Priel D, Chan KC, Fox SD, Gallin JI, Kuhns DB, Malech HL. 2010. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. Blood 116:1755-1760. http://dx.doi.org/10.1182/blood-2009-07-233734.
35. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ. 2001. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:842-853. http://dx.doi.org/10.1046/j.1471-4159.2001.00498.x.
36. Ibana JA, Belland RJ, Zea AH, Schust DJ, Nagamatsu T, AbdelRahman YM, Tate DJ, Beatty WL, Aiyar AA, Quayle AJ. 2011. Inhibition of indoleamine 2, 3-dioxygenase activity by levo-1-methyl tryptophan blocks gamma interferon-induced Chlamydia trachomatis persistence in human epithelial cells. Infect Immun 79:4425-4437. http://dx.doi.org/10.1128/IAI.05659-11.
37. Dekker LV, Segal AW. 2000. Perspectives: signal transduction. Signals to move cells. Science 287:982-983, 985.
38. Lokuta MA, Huttenlocher A. 2005. TNF-α promotes a stop signal that inhibits neutrophil polarization and migration via a p38 MAPK pathway. J Leukoc Biol 78:210-219. http://dx.doi.org/10.1189/jlb.0205067.
39. Munn DH, Mellor AL. 2013. Indoleamine 2, 3-dioxygenase and metabolic control of immune responses. Trends Immunol 34:137-143. http://dx.doi.org/10.1016/j.it.2012.10.001.
40. Barouki R, Aggerbeck M, Aggerbeck L, Coumoul X. 2012. The aryl hydrocarbon receptor system. Drug Metabol Drug Interact 27:3-8.
41. Hunstad DA, Justice SS. 2010. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol 64: 203-221. http://dx.doi.org/10.1146/annurev.micro.112408.134258.
42. Olson PD, Hunstad DA. 2016. Subversion of host innate immunity by uropathogenic Escherichia coli. Pathogens 5:pii:E2. http://dx.doi.org/10.3390/pathogens5010002.
43. El-Zaatari M, Chang YM, Zhang M, Franz M, Shreiner A, McDermott AJ, van der Sluijs KF, Lutter R, Grasberger H, Kamada N, Young VB, Huffnagle GB, Kao JY. 2014. Tryptophan catabolism restricts IFNγ-expressing neutrophils and Clostridium difficile immunopathology. J Immunol 193:807-816. http://dx.doi.org/10.4049/jimmunol.1302913.
44. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. 2010. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185: 3190-3198. http://dx.doi.org/10.4049/jimmunol.0903670.
45. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T. 2010. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynureninedependent mechanism. Proc Natl Acad Sci U S A 107:19961-19966. http://dx.doi.org/10.1073/pnas.1014465107.
46. Wang T, Wyrick KL, Pecka MR, Wills TB, Vorderstrasse BA. 2012. Mechanistic exploration of AhR-mediated host protection against Streptococcus pneumoniae infection. Int Immunopharmacol 13:490-498. http://dx.doi.org/10.1016/j.intimp.2012.05.008.
47. Wheeler JL, Martin KC, Lawrence BP. 2013. Novel cellular targets of AhR underlie alterations in neutrophilic inflammation and inducible nitric oxide synthase expression during influenza virus infection. J Immunol 190:659-668. http://dx.doi.org/10.4049/jimmunol.1201341.
48. Julliard W, Fechner JH, Mezrich JD. 2014. The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front Immunol 5:458.
49. Dorward DA, Lucas CD, Chapman GB, Haslett C, Dhaliwal K, Rossi AG. 2015. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation.AmJ Pathol 185:1172-1184. http://dx.doi.org/10.1016/j.ajpath.2015.01.020.
50. Olson PD, Hruska KA, Hunstad DA. 8 October 2015. Androgens enhance male urinary tract infection severity in a new model. J Am Soc Nephrol http://dx.doi.org/10.1681/ASN.2015030327.
51. Lau ME, Danka ES, Tiemann KM, Hunstad DA. 2014. Bacterial lysis liberates the neutrophil migration suppressor YbcL from the periplasm of uropathogenic Escherichia coli. Infect Immun 82:4921-4930. http://dx.doi.org/10.1128/IAI.01838-14.
52. Lau ME, Loughman JA, Hunstad DA. 2012. YbcL of uropathogenic Escherichia coli suppresses transepithelial neutrophil migration. Infect Immun 80:4123-4132. http://dx.doi.org/10.1128/IAI.00801-12.